Get all premium features to the best stock analysis tool

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, March 25, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.

LEVI & KORSINSKY, LLP: GRAIL (GRAL) GUIDED TO 2030 CASH RUNWAY WHILE KEY TRIAL RISK WENT UNADDRESSED

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time NEW YORK, March 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders who lost money on GRAL are encouraged to submit their information now.

GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026.

Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time